Michael Bös

CSO

  Dr. Bös has extensive experience in Drug Discovery and Development. He received his PhD in medicinal chemistry from the University of Vienna. After postdoctoral studies at the ETH Zurich with Prof. D. Seebach and at Colorado State University in Fort Collins (USA) with Prof. A. I. Meyers, he joined F. Hoffmann-La Roche in Basel, Switzerland, as a medicinal chemist in 1986. At Roche, Dr. Bös was involved in a number of projects targeting diseases of the CNS such as depression, obsessive compulsive disorder and Alzheimer’s disease. As an exchange scientist at Roche in Nutley, New Jersey (1989-1990), he worked on Thyrotropine Releasing Hormone where he applied computer-assisted modelling for the design of new non-peptidic scaffolds. In 1999 he moved to Montreal to take up the position of Director of Chemistry at Boehringer Ingelheim (Canada) Ltd. During his 7 year tenure as head of a department of 58 chemists (dealing with medicinal chemistry, analytical chemistry and structural chemistry) the first HCV NS3 protease inhibitor (BILN 2061) moved into clinical development and 6 compounds targeting HCV and HIV were granted start of development.